NYSE$MDT

Medtronic PLC · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Medtronic's Q1 2021 financial results reflected a decrease in revenue and EPS due to the impact of the COVID-19 pandemic, but showed signs of recovery with improving procedure volumes and innovative product contributions.

Medtronic reported a 13% decrease in Q1 revenue to $6.507 billion, with a GAAP diluted EPS of $0.36 and a non-GAAP diluted EPS of $0.62. The results were impacted by the COVID-19 pandemic, but the company saw a faster than expected recovery with improving procedure volumes.

  • Q1 revenue decreased by 13% as reported, and approximately 17% organic.
  • GAAP diluted EPS was $0.36, while non-GAAP diluted EPS was $0.62.
  • Procedure volumes began to recover around the world.
  • The company is leveraging its pipeline of innovative products to drive share gains.

Headline financials

Total Revenue

$6.51B

Previous: $7.49B-13.2%
EPS (adj)

$0.62

Previous: $1.26-50.8%
Capital Expenditures

-$334M

Previous: -$301M-11.0%
Free Cash Flow

-$56M

Previous: $1.21B-104.6%
Net Income

$487M

Previous: $864M-43.6%
Operating Income

$673M

Previous: $1.49B-54.7%
Gross Profit

$4B

Previous: $5.13B-21.9%
Cash & Equivalents

$6.5B

Previous: $5.08B+27.9%
Total Assets

$93.9B

Previous: $91.3B+2.9%
Stock-Based Comp

$70M

Previous: $61M+14.8%

Revenue & EPS history

Medtronic · Revenue · Quarterly

$6.51B

Q1 2021-13.2%vs Q1 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Medtronic · $6.1B total across 8 segments · Q1 2021

  • Cardiac Rhythm & Heart Failure
    $1.25B-9.8%
  • Surgical & Endoscopy
    $1.08B-23.8%
  • Cranial & Spinal Technologies
    $944M-10.1%
  • Coronary & Peripheral Vascular
    $780M-17.1%
  • Acute Care & Monitoring
    $720M+5.4%
  • Diabetes
    $562M-5.1%
  • Specialty Therapies
    $453M-19.5%
  • Neuromodulation
    $314M-21.1%

Forward guidance

Given the uncertainty on near-term financial results caused by the COVID-19 pandemic, the company is not providing formal annual or quarterly financial guidance at this time.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.2%

Avg return

Earnings day

-0.0%

Avg return

5 days after

-1.4%

Avg return

30 days after

57%

37 / 65 earnings

Positive

+6.2%

Q1 2019

Best reaction

-7.3%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-2.8%-2.6%-12.7%
Q2 2026+3.9%+5.1%+2.3%
Q1 2026-3.1%-0.1%+3.0%
Q4 2025-2.2%-6.6%-0.0%
Q3 2025-7.3%-3.1%-1.7%
Q2 2025-4.0%-1.6%-8.7%
Q1 2025+3.2%+4.2%+5.5%
Q4 2024-4.0%-4.4%-4.8%
Q3 2024+1.8%+1.5%-1.2%
Q2 2024+4.3%+5.1%+9.0%
Q1 2024+2.5%+0.7%-1.4%
Q4 2023-6.9%-5.7%-0.0%
Q3 2023+0.4%-1.5%-8.5%
Q2 2023-4.0%-3.9%-6.3%
Q1 2023-4.1%-3.9%-10.2%
Q4 2022-6.1%-5.1%-14.5%
Q3 2022+2.4%+5.2%+5.7%
Q2 2022-2.1%-5.0%-12.0%
Q1 2022+4.7%+4.1%+1.7%
Q4 2021+0.3%-0.8%+2.8%
Q3 2021+2.6%+1.1%+0.7%
Q2 2021+2.1%+3.3%+2.8%
Q1 2021+3.9%+7.7%+1.1%
Q4 2020-3.4%-0.9%-4.3%
Q3 2020-3.0%-3.5%-32.5%
Q2 2020+0.5%-0.4%+2.0%
Q1 2020+3.5%+1.8%+6.6%
Q4 2019+4.8%+2.9%+12.0%
Q3 2019+0.6%+1.6%-0.2%
Q2 2019+2.9%+1.8%-0.5%
Q1 2019+6.2%+6.1%+8.3%
Q4 2018+1.2%+0.2%+1.8%
Q3 2018-3.1%-3.5%-6.2%
Q2 2018+4.4%+5.5%+3.3%
Q1 2018-4.5%-5.3%-4.8%
Q4 2017+0.5%+0.2%+5.3%
Q3 2017+0.9%+2.7%+2.5%
Q2 2017-6.0%-6.3%-11.0%
Q1 2017-0.1%+0.2%+1.2%
Q4 2016-1.4%+1.5%+6.2%
Q3 2016-3.6%
Q2 2016+2.7%
Q1 2016-3.6%
Q4 2015+0.2%
Q3 2015+4.3%
Q2 2015+3.7%
Q1 2015+1.1%
Q4 2014-1.0%
Q3 2014-1.2%
Q2 2014-2.4%
Q1 2014-2.6%
Q4 2013+3.3%
Q3 2013-5.0%
Q2 2013+1.6%
Q1 2013+1.2%
Q4 2012+2.1%
Q3 2012+2.0%
Q2 2012-6.5%
Q1 2012-3.2%
Q4 2011+1.5%
Q3 2011+1.4%
Q2 2010-0.2%
Q1 2010+1.5%
Q4 2010+0.7%
Q3 2009+0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro